Electronic Medical Record–Based Nudge Intervention to Increase Comprehensive Molecular Genotyping in Patients With Metastatic Non–Small Cell Lung Cancer: Results From a Prospective Clinical Trial
- 1 December 2024
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 20 (12) , 1620-1628
Abstract
PURPOSE: Less than half of the patients with newly diagnosed metastatic non–small cell lung cancer (NSCLC) undergo comprehensive molecular testing. We designed an electronic medical record (EMR)–based “nudge intervention” to prompt plasma-based molecular testing at the time of initial medical oncology consultation. METHODS: A nonrandomized prospective trial was conducted at the University of Pennsylvania's academic practice and two affiliated community practices. Molecular genotyping was performed by tissue- and/or plasma-based next generation sequencing methods. Comprehensive testing was defined as testing for EGFR , ALK , BRAF , ROS1 , MET , RET , KRAS , and NTRK . Guideline-concordant treatment was defined as the use of the appropriate first-line (1L) therapy as per the National Comprehensive Cancer Network (NCCN) guidelines. Proportion of patients with comprehensive molecular genotyping results available at any time, molecular results available before 1L therapy, and guideline-concordant 1L treatment were compared between the preintervention and postintervention cohorts using Fisher's exact test or Pearson's chi-squared test. RESULTS: Five hundred and thirty-three patients were included, 376 in the preintervention cohort and 157 in the postintervention cohort. After implementation of the EMR-based nudge, a higher proportion of patients underwent comprehensive molecular testing in the postintervention versus the preintervention cohort (100% v 88%, P = <.001), had results of comprehensive molecular testing available before initiating 1L treatment (97.3% v 91.6%, P = .026), and received NCCN guideline-concordant care (89.8% v 78.2%, P = .035). CONCLUSION: Across three practice sites in a large health system, implementation of a provider team–focused EMR-based nudge intervention was feasible, and led to a higher number of patients with NSCLC undergoing comprehensive molecular genotyping. These findings demonstrate that behavioral nudges can promote molecular testing and should be studied further as a tool to improve guideline-concordant care in both community and academic sites.Keywords
This publication has 15 references indexed in Scilit:
- Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology NetworkLung Cancer, 2022
- Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practiceNature Reviews Clinical Oncology, 2020
- Designing Nudges for Success in Health CareAMA Journal of Ethics, 2020
- The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung CancerJournal of Thoracic Oncology, 2020
- Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung CancerClinical Cancer Research, 2019
- Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non–Small Cell Lung Cancer Using a Clinicogenomic DatabaseJAMA, 2019
- Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung CancerJAMA Oncology, 2019
- Association between Electronic Medical Record Implementation of Default Opioid Prescription Quantities and Prescribing Behavior in Two Emergency DepartmentsJournal of General Internal Medicine, 2018
- Using Active Choice Within the Electronic Health Record to Increase Influenza Vaccination RatesJournal of General Internal Medicine, 2017
- Generic Medication Prescription Rates After Health System–Wide Redesign of Default Options Within the Electronic Health RecordJAMA Internal Medicine, 2016